Results 41 to 50 of about 656,371 (370)

Which are the most promising targets for minimal residual disease-directed therapy in acute myeloid leukemia prior to allogeneic stem cell transplant?

Haematologica, 2019
Minimal residual disease has emerged as an important prognostic factor for relapse and survival in acute myeloid leukemia. Eradication of minimal residual disease may increase the number of patients with long-term survival; however, to date, strategies ...
Brian Ball, Eytan M. Stein
doaj   +1 more source

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.

Blood, 2018
Approximately 30% to 50% of adults with acute lymphoblastic leukemia (ALL) in hematologic complete remission after multiagent therapy exhibit minimal residual disease (MRD) by reverse transcriptase-polymerase chain reaction or flow cytometry.
N. Gökbuget, H. Dombret, M. Bonifacio, A. Reichle, C. Graux, C. Faul, H. Diedrich, M. Topp, M. Brüggemann, H. Horst, V. Havelange, J. Stieglmaier, Hendrik Wessels, V. Haddad, J. Benjamin, G. Zugmaier, D. Nagorsen, R. Bargou   +17 more
semanticscholar   +1 more source

Network location and clustering of genetic mutations determine chronicity in a stylized model of genetic diseases [PDF]

Sci Rep 12, 19906 (2022), 2022
In a highly simplified view, a disease can be seen as the phenotype emerging from the interplay of genetic predisposition and fluctuating environmental stimuli. We formalize this situation in a minimal model, where a network (representing cellular regulation) serves as an interface between an input layer (representing environment) and an output layer ...
arxiv   +1 more source

Liquid Biopsy to Detect Minimal Residual Disease: Methodology and Impact

Cancers, 2021
Simple Summary The field of liquid biopsy is rapidly evolving. Techniques that improve accuracy are constantly being developed, and clinicians increasingly use liquid biopsy as a tool to guide their clinical practice.
N. Honoré, R. Galot, C. van Marcke, N. Limaye, J. Machiels   +4 more
semanticscholar   +1 more source

Electrostatics in the Stability and Misfolding of the Prion Protein: Salt Bridges, Self-Energy, and Solvation [PDF]

Biochemistry and Cell Biology 2010, Volume 88, Number 2, Pages 371 - 381, 2010
Using a recently developed mesoscopic theory of protein dielectrics, we have calculated the salt bridge energies, total residue electrostatic potential energies, and transfer energies into a low dielectric amyloid-like phase for 12 species and mutants of the prion protein.
arxiv   +1 more source

Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia

Haematologica, 2017
Our aim was to improve outcome prediction after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia by combining cytogenetic and molecular data at diagnosis with minimal residual disease assessment by multicolor flow-cytometry at
Betül Oran, Jeff L. Jorgensen, David Marin, Sa Wang, Sairah Ahmed, Amin M. Alousi, Borje S. Andersson, Qaiser Bashir, Roland Bassett, Genevieve Lyons, Julianne Chen, Katy Rezvani, Uday Popat, Partow Kebriaei, Keyur Patel, Gabriela Rondon, Elizabeth J. Shpall, Richard E. Champlin   +17 more
doaj   +1 more source

Liquid biopsies and minimal residual disease in lymphoid malignancies

Frontiers in Oncology, 2023
Minimal residual disease (MRD) assessment using peripheral blood instead of bone marrow aspirate/biopsy specimen or the biopsy of the cancerous infiltrated by lymphoid malignancies is an emerging technique with enormous interest of research and ...
Maroun Bou Zerdan, Joseph Kassab, Ludovic Saba, Elio Haroun, Morgan Bou Zerdan, Sabine Allam, Lewis Nasr, Walid Macaron, Mahinbanu Mammadli, Sarah Abou Moussa, Chakra P. Chaulagain   +10 more
doaj   +1 more source

Assessment of Minimal Residual Disease in Ewing Sarcoma [PDF]

, 2012
Advances in molecular pathology now allow for identification of rare tumor cells in cancer patients. Identification of this minimal residual disease is particularly relevant for Ewing sarcoma, given the potential for recurrence even after complete ...
Marmer, Daniel, Smolarek, Teresa A., Sumegi, Janos, Wagner, Lars M.   +3 more
core   +3 more sources

Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences

Clinical Cancer Research, 2021
Purpose: Sensitive methods for risk stratification, monitoring therapeutic efficacy, and early relapse detection may have a major impact on treatment decisions and patient management for stage III colorectal cancer patients.
T. Henriksen, N. Tarazona, A. Frydendahl, T. Reinert, F. Gimeno-Valiente, J. Carbonell-Asins, Shruti Sharma, D. Renner, D. Hafez, D. Roda, M. Huerta, S. Roselló, A. H. Madsen, U. S. Løve, P. V. Andersen, O. Thorlacius-Ussing, L. Iversen, K. A. Gotschalck, H. Sethi, A. Aleshin, A. Cervantes, C. Andersen   +21 more
semanticscholar   +1 more source

Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration

Clinical Cancer Research, 2021
The development of novel agents has transformed the treatment paradigm for multiple myeloma, with minimal residual disease (MRD) negativity now achievable across the entire disease spectrum.
K. Anderson, D. Auclair, S. Adam, A. Agarwal, Melissa Anderson, H. Avet-Loiseau, M. Bustoros, Jessica Chapman, Dana E. Connors, Ajeeta B. Dash, A. Di Bacco, Ling Du, T. Facon, J. Flores-Montero, F. Gay, I. Ghobrial, N. Gormley, I. Gupta, H. Higley, J. Hillengass, B. Kanapuru, D. Kazandjian, G. Kelloff, I. Kirsch, B. Kremer, O. Landgren, Elizabeth D Lightbody, O. Lomas, S. Lonial, M. Mateos, R. Montes de Oca, Lata Mukundan, N. Munshi, E. O’Donnell, A. Órfão, B. Paiva, Reshma Patel, Trevor J Pugh, K. Ramasamy, J. Ray, M. Roshal, J. Ross, C. Sigman, K. Thoren, S. Trudel, G. Ulaner, N. Valente, B. Weiss, E. Zamagni, Shaji K. Kumar   +49 more
semanticscholar   +1 more source